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Immediate Adaptations to Post-Stroke Walking Performance Using a Hip 
Wearable Robotic Exoskeleton 
 
Abstract  
Objective: To examine the immediate effects of a hip-assistive wearable robotic exoskeleton on 
clinical walking performance, walking energetics, gait kinematics, and corticomotor excitability 
in individuals with stroke. 
 
Design: Randomized cross-over trial. 
 
Setting: Research laboratory of a rehabilitation hospital. 
 
Participants: Twelve individuals (4F/8M, mean age 57.8±7.2) with chronic hemiparetic stroke. 
 
Interventions: Honda’s Stride Management Assist (SMA) exoskeleton, which provides torque-
based flexion and extension assistance at the hip joints during walking. 
 
Main Outcome Measures: The primary outcome measure was change in self-selected walking 
speed with the device off vs. with the device on. Secondary outcome measures included changes 
in clinical endurance, energy expenditure, kinematics, and corticomotor excitability of lower 
limb muscles. 
 
Results: In a single session using the device, participants exhibited adaptations over most 
outcome measures. Self-selected walking speed and peak treadmill speed increased, while 
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oxygen consumption rate decreased during overground and treadmill endurance tests. More 
symmetric walking patterns were observed during treadmill walking. Changes in corticomotor 
excitability were highly variable among participants, with a non-significant increase in 
excitability for the paretic rectus femoris. 
 
Conclusions: The SMA hip exoskeleton causes immediate positive adaptations in walking 
performance in individuals with stroke when the device is in use. 
 
Key words: intervention; outcomes research; wearable robotics; transcranial magnetic 
stimulation 
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Abbreviations 
 
6MWT Six-Minute Walk Test 
ACC  Angular coefficient of correspondence 
BWSTT Body-weight supported treadmill training 
EMG  Electromyography 
FV  Fast velocity 
FWHM Full Width at Half-Maximum 
MEP  Motor-evoked potential 
MCID  Minimal clinically important difference 
SMA  Stride Management Assist 
SSV  Self-selected velocity 
RF  Rectus femoris 
TA  Tibialis anterior 
TM  Treadmill 
TMS  Transcranial Magnetic Stimulation 
VO2  Oxygen consumption rat
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Introduction 1 
Deficits in sensorimotor control and subsequent disability in ambulation are common 2 
manifestations of stroke. Individuals with stroke experience reduced range of motion, 3 
insufficient forward and backward propulsion, insufficient weight shift between the non-paretic 4 
and paretic legs, muscle atrophy, weakness, and spasticity, resulting in compensatory 5 
mechanisms and asymmetrical walking patterns [1-3]. Abnormal hip and pelvis movements 6 
compensate for ineffective knee progression and foot clearance. These altered compensatory 7 
techniques result in poor walking mechanics, high-energy expenditure, and reduced gait speed 8 
[4-6], which contribute to limited community mobility and social interaction [7-8]. As such, 9 
improving walking function is often cited as a primary rehabilitation goal for this population [9-10 
14]. 11 
 12 
Current therapeutic practices emphasize increasing step count to improve post-stroke 13 
ambulation. Body-weight supported treadmill training (BWSTT) and robot-assisted gait have 14 
shown positive effects on walking ability and function [15-19]. However, in a rehabilitation 15 
setting these methods are typically limited to providing stepping practice on a treadmill or 16 
constrained environment, and do not provide the challenge and specificity of walking practice 17 
over-ground. Unconstrained robotic exoskeletons are promising tools to facilitate gait 18 
rehabilitation, as well as supporting community mobility and activities of daily living beyond the 19 
clinical environment. At present, a substantial amount of wearable robotics research targets 20 
powered lower limb exoskeletons for severe impairments or joint-specific devices, such as the 21 
foot and ankle actuation systems [19-22]. Soft robotics has also become an emerging area of 22 
research [23], where the devices have little to no rigid material. Preliminary results indicate that 23 
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one such device has the potential to reduce metabolic cost during walking [24]. However, there 24 
are very few studies that have looked at the impact of a light-weight hip wearable robotic 25 
exoskeleton on improving walking performance in the stroke population suffering from mild-26 
moderate gait deficits.  27 
 28 
The Stride Management Assist (SMA) robotic device was developed by Honda R&D 29 
Corporation to enhance walking performance and increase the community mobility and social 30 
interaction in elderly adults and patients with gait disorders [25-27]. The SMA provides torque-31 
driven assistance to voluntary movement at the hip joints, augmenting hip flexion and extension 32 
independently for each side. In the elderly population, three-month SMA use significantly 33 
improved walking speed and reduced glucose metabolism in lower limb muscles [27]. Similarly, 34 
previous studies in young adults showed that the SMA increased the walking ratio (step 35 
length/cadence) [25] and reduced the metabolic cost of walking over a single session [28]. In 36 
individuals with stroke, 6-8 weeks of gait training with the SMA improved clinical outcomes, 37 
stepping activity, and corticomotor excitability of the rectus femoris [29], as well as gait 38 
kinematics [30], similar to or better than intensity-matched functional gait training without the 39 
exoskeleton. At present, the time-course of these improvements is unclear, as are the relative 40 
contributions of the device and dosage. It remains to be seen how the SMA affects clinical 41 
outcomes in a single session for a neurologically impaired population. The impact of a single 42 
training session is of interest to therapists and clinicians so they can quickly determine whether 43 
an intervention is appropriate for an individual patient. This would help them design training 44 
dosages (or decide to pursue other interventions) to maximize and maintain clinical outcomes for 45 
each patient.  46 
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The purpose of this preliminary study was to examine the immediate effects of walking with the 47 
SMA on functional walking ability in individuals post-stroke. We tested the hypothesis that a 48 
single session of walking with the SMA would elicit immediate adaptations in gait, including 49 
walking speed, energetics, kinematics, and corticomotor excitability of lower limb muscles. We 50 
measured gait outcomes while the SMA was both active and inactive, to account for potential 51 
secondary effects of wearing the exoskeleton on gait (e.g. added mass, physical structure, and 52 
placebo effects). 53 
 54 
Methods 55 
Participants 56 
Twelve individuals with chronic unilateral stroke were recruited (4F/8M, mean age 57.8±7.2). 57 
Demographic information for all participants is listed in Table 1. All participants were able to 58 
walk independently on level ground, and were allowed to use assistive devices or bracing as 59 
needed during training and testing. The study was approved by the IRB at the Northwestern 60 
University, and all participants provided written consent.  61 
 62 
Inclusion criteria for the study were: 1) history of one unilateral, supratentorial, ischemic or 63 
hemorrhage stroke, with lesion location confirmed by radiographic findings, 2) gait speed less 64 
than 0.8 m/s (limited community ambulators), as measured through a 10-Meter Walk Test, and 65 
3) medically stable with medical clearance to participate (absence of concurrent illness, 66 
including unhealed decubiti, infection, cardiopulmonary disease, osteoporosis, active 67 
heterotrophic ossification, peripheral nerve damage in the lower limbs, and a history of traumatic 68 
head injury). Exclusion criteria for the study were: 1) body weight of more than 250 lbs, which is 69 
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the limit of most counter-weight safety systems, and 2) pregnancy, due to potential forces at 70 
trunk from BWS or pelvic assistance. Exclusion criteria for measuring corticomotor excitability 71 
using Transcranial Magnetic Stimulation (TMS) were: pacemaker, metal implants in the head 72 
region, history of epilepsy or seizures, skull fractures or skull deficits, concussion within the last 73 
6 months, unexplained recurring headaches, medications that lower seizure threshold, and 74 
pregnancy. 75 
 76 
SMA Device 77 
The Stride Management Assist (SMA) is a robotic device developed by Honda R&D 78 
Corporation (Japan), which assists hip flexion and extension for each leg independently. The 79 
SMA is worn around the waist like a belt, with 2 brushless DC motors at the hip joints that 80 
generate assistive torque, transmitted to the legs via frames at the mid-thigh. The device is 81 
operated using custom software on a tablet, which allows the user or a physical therapist to 82 
change assist settings while the user is wearing the SMA. The device weighs 2.8 kg, with a 83 
rechargeable lithium ion battery. The operation time is approximately 2 hours on a single charge 84 
for continuous walking at 4.5 km/hour. 85 
 86 
The SMA control architecture uses a mutual rhythm scheme to influence the user’s walking 87 
patterns. Angle sensors embedded in the SMA actuators detect the user’s hip joint angles 88 
throughout the gait cycle. These angles are input to the SMA controller, which calculates hip 89 
joint angle symmetry. The device then generates assistive torques at specific instances during the 90 
gait cycle to regulate these walking patterns. The user initiates walking and controls their 91 
walking speed. After initial contact, the extensor torque initiates and reaches its peak just before 92 
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mid-stance. The SMA then switches to flexion assist during terminal stance. The flexor torque 93 
reaches its peak around initial swing. Finally, the SMA switches to extension assist during 94 
terminal swing, and the cycle repeats. Peak torque values for flexion and extension ultimately 95 
depend on user input. While the SMA is capable of outputting a maximum of 6 Nm of assist 96 
torque, peak torque values are contingent upon user hip joint dynamics determined from the 97 
angle sensors. The SMA automatically manipulates the walking motion to increase walk ratio 98 
(step length/cadence) providing torque assistance during hip flexion and extension movements 99 
when walking is initiated. For example, if the SMA detects hip joint angle asymmetry, then the 100 
SMA assist pattern follows a more flexion dominant curve for the leg with shorter stride length, 101 
in an attempt to better support the user. Depending on user hip joint angles, the peak flexor 102 
torque may be less than 6 Nm. The SMA is designed to provide assistance only in the sagittal 103 
plane; it does not restrict movement in other directions.  104 
 105 
Randomization and training protocol 106 
A randomized cross-over design (Fig. 1) was implemented in this study. Participants were 107 
stratified to either a device-on (ON) or device-off (OFF) condition. Outcome measures were 108 
collected under this condition in a single session. After one week, the participant crossed-over to 109 
the other condition and the same measures were collected in a single session. Because all 110 
participants completed both conditions, they acted as their own controls. All participants were 111 
acclimated to the device with a single 30-45-minute training session with a licensed physical 112 
therapist. In this session, therapists introduced the device and participants practiced walking with 113 
the device in a 12-m long hallway, with rests as needed. Participants first walked with the device 114 
donned but turned off, then the therapist turned the device on and provided contact guarding until 115 
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the participant felt comfortable walking independently under supervision. Once the therapist was 116 
satisfied that the participant could walk safely, independently, and comfortably with the device 117 
under supervision, the participant was randomly assigned to the ON or OFF condition without 118 
being told to which group they were assigned. At least one week was required between 119 
conditions to allow for wash-out. 120 
 121 
--- [Fig. 1] --- 122 
 123 
Testing and evaluation protocol 124 
The primary outcome measure was change in self-selected walking speed between the ON and 125 
OFF conditions. The secondary outcome measures were changes in fast walking speed, 126 
endurance, energetic efficiency, kinematics, and corticomotor excitability of paretic lower limb 127 
muscles between the two conditions. The measures and procedures are described below. 128 
 129 
• Self-selected walking velocity (SSV) and fastest walking velocity (FV): Participants 130 
walked in a straight line on an instrumented walkway (GaitMat II®, Equitest Inc, 131 
Chalfont) using their self-selected pace and fastest safe pace. Three trials were averaged 132 
at each speed. 133 
 134 
• Six-minute walk test (6MWT): Participants were instructed to cover as much distance as 135 
possible during six minutes. They walked up and down a straight hallway, and distance 136 
was measured. 137 
 138 
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• Graded treadmill test: Participants walked on an instrumented treadmill with harness but 139 
no body weight support. Testing started at 0.5 km/h and was increased in 0.5 km/h 140 
increments every 3 minutes until peak treadmill speed was achieved (identified as ability 141 
to sustain speed for ≥1min without stopping the treadmill). 142 
 143 
• Energetic efficiency: Oxygen consumption rate (VO2) were measured during the six-144 
minute walk test and graded treadmill test from a portable metabolic system (K4b2, 145 
CosMed Srl., Rome, Italy). Baseline measures were obtained during five minutes of 146 
sitting immediately prior to walking.  147 
 148 
• Kinematic measures during SSV treadmill walking: Lower extremity kinematic data were 149 
collected using a motion analysis system (Motion Analysis Corp, Santa Rosa, CA). The 150 
system includes six strategically positioned charge-coupled device video cameras 151 
(VC491; Oxford Metrics), a minicomputer (PDP 11/73; Digital Equipment, Maynard, 152 
MA), and software (Visual 3D, C-motion; Germantown, MD) for the collection and 153 
analysis of the data. Twenty-one spherical reflective markers, one inch (25.4 mm) in 154 
diameter, were placed over predetermined anatomical landmarks on the trunk and the 155 
upper and lower extremities using the modified Cleveland Clinic Marker Set (Motion 156 
Analysis Corporation, Santa Rosa, CA). The SMA and other reflective surfaces were 157 
covered with non-reflective tape. Participants walked on a treadmill at the speed 158 
determined from the over-ground SSV measure. A harness attached to the suspension 159 
system was used for fall prevention, with no body weight support. Position coordinates 160 
for the markers on both sides of the body were recorded simultaneously at 100 Hz with 161 
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use of the phase-locked cameras. This allowed for the three-dimensional reconstruction 162 
of the motion of all of the major joints of the upper and lower extremities.  163 
 164 
• Angular coefficient of correspondence (ACC) [31-32]: hip/knee kinematics were 165 
assessed bilaterally to determine the consistency of sagittal plane hip/knee trajectories, 166 
calculated by vector coding. The difference between each successive motion frame for 167 
hip angle values and knee angle values was transformed into a vector, with both direction 168 
and magnitude, using the methods described in [31]. This vector was computed in 1% 169 
increments of the normalized gait cycle. The ACC is an average of all vector lengths, 170 
representing the degree of consistency between hip and knee angles across multiple gait 171 
cycles. An ACC of 1.0 signifies perfect consistency, wherein the relative motion between 172 
the hip and knee are in complete agreement over all gait cycles. An ACC of 0.0 signifies 173 
no consistency between hip and knee angles. Positive changes in ACC indicate improved 174 
coordination of a limb. 175 
 176 
• Full Width at Half-Maximum (FWHM) [33]: the periodogram of stepping frequency was 177 
created from the data obtained using an electronic goniometer at the hip joint. Maximum 178 
power was determined at the appropriate frequency (consistent with cadence estimates). 179 
The width of the peak at half-maximum power was then calculated in Hz. Low values of 180 
FWHM indicate rhythmic and periodic stepping, whereas high values suggest erratic 181 
stepping, such as stumbling or foot dragging [34]. Negative changes in FWHM indicate 182 
improved periodicity in stepping patterns. 183 
 184 
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• Corticomotor excitability (CME): motor-evoked potentials (MEPs) estimated excitability 185 
of the paretic rectus femoris (RF – hip flexor and knee extensor) and tibialis anterior (TA 186 
– ankle dorsiflexor) during SSV treadmill walking. MEPs were induced using 187 
transcranial magnetic stimulation (TMS), A double cone coil (Magstim 200, Wales, UK) 188 
delivered TMS at a minimum frequency of 0.25 Hz, localized on the muscle hotspot in 189 
accordance with [35]. A hotspot is the location on motor cortex producing the maximum 190 
MEP response for the contralateral muscle at the lowest stimulator intensity. For RF, 191 
MEPs were evoked at 120% active motor threshold, determined during points in the gait 192 
cycle that corresponded to the muscle’s peak activation. For TA, motor excitability was 193 
probed during late swing to maintain consistency with previous studies [36-37]. During 194 
walking, electromyography (EMG) containing 10 MEPs per muscle was recorded during 195 
the ON and OFF conditions. The averaged MEP area as a percentage of background 196 
activity was calculated for each response. For each participant, we then calculated a 197 
percentage normalized to the change in the MEP amplitude for each muscle with the 198 
device ON compared to when the device was OFF. 199 
 200 
TMS Protocol 201 
A previously established TMS protocol was employed to obtain measures of CME during 202 
walking [36-37]. A pulley system supported the TMS coil cable over the participant's head. Coil 203 
position was primarily maintained by Velcro® tapes secured between the inside of the coil and 204 
the top of a linen cap. Slight adjustments to the coil position were made until MEPs ≥ 0.4 mV 205 
were elicited from TA with minimal TMS intensity. A chin strap was then attached to the coil, 206 
and foam pads were inserted between the head and the lateral aspects of the coil to increase 207 
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stability of the placement. This allowed subjects to walk naturally and move their head freely 208 
between trials without disturbing the coil location. Coil position was checked frequently during 209 
data collection, and no changes were detected for any participant. 210 
 211 
Following data collection, pre-trigger root mean square EMG amplitude (mV r.m.s.) was 212 
calculated for the 40 ms of data just prior to the stimulus, and MEP amplitude (mV peak-to-213 
peak) was calculated using custom code in Matlab (MathWorks, Natick, MA). 214 
 215 
To match for similar levels of background activity across time periods, responses were discarded 216 
if they were associated with high or low amplitude pre-trigger EMG to bring the range and mean 217 
pre-trigger EMG amplitudes for each subject and muscle to within 2%. After this processing, 218 
typically 10 responses remained for each condition. 219 
 220 
Statistical Analysis 221 
Paired sample t-tests were performed for all raw measures to compare the ON and OFF 222 
conditions, since all participants were their own controls and the test of normalcy showed a 223 
normal distribution of the data. For CME, one-sample t-tests were performed to compare the 224 
percentage change in CME to 0. The significance level was set at p<0.05. The 95% confidence 225 
intervals are reported for the difference between ON and OFF conditions. All statistics were 226 
performed in SPSS Version 20 (IBM Co., NY). 227 
 228 
Sample Size Estimation 229 
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Sample size was chosen using a superiority test with cross-over design [38]. The superiority 230 
margin was taken as the suggested Minimal Clinically Important Difference (MCID) for the 231 
primary outcome, walking speed. MCID for self-selected walking speed for a stroke population 232 
was taken as 0.06 m/s [39]. To achieve 80% power with a significance level of 0.05 and an 233 
estimated population variance of 0.01 m/s, the sample size is 9 participants.  234 
 235 
Results 236 
Changes in the outcome measures between the ON and OFF conditions are given in Table 2 for 237 
each participant. The primary outcome measure, self-selected walking speed, is shown in Figure 238 
2 for the baseline (not wearing the device), and with the device OFF and ON. Paired t-tests 239 
reveal no significant difference in SSV between baseline and the OFF condition (p=0.13). Self-240 
selected walking speed increased by 8.6% (SEM 2.8) with the SMA in the ON condition (Fig. 241 
3A; p=0.012; 95% CI = [0.008, 0.097] m/s). There was no difference in fast velocity (p=0.96; 242 
95% CI = [-0.061,0.058] m/s).  243 
 244 
--- [Fig. 2] --- 245 
 246 
Peak treadmill speed tolerated also increased during the graded treadmill test (Fig. 3B; p<0.001; 247 
95% CI = [0.08, 0.14] m/s). Average distance walking during the 6MWT increased, though this 248 
difference was non-significant (p=0.061; 95% CI = [-1.8, 66.5] m). Maximum and average VO2 249 
costs decreased in the graded treadmill test (p=0.024; 95% CI = [-0.14, 0.03] mL/kg/km) and 250 
6MWT (p=0.019; 95% CI = [-67.6, -2.3] mL/kg/km), respectively (Fig. 3C).  251 
 252 
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Intralimb kinematic variability, measured using average ACC, increased on the paretic and non-253 
paretic sides with the SMA ON (Fig. 3D; p’s<0.001; 95% CI = [0.030, 0.096] paretic, [0.093, 254 
0.12] non-paretic). Stepping periodicity, measured using FWHM, also decreased in both the 255 
affected and unaffected sides of the stroke participants (Fig. 3E; p’s<0.017; 95% CI = [-0.017, -256 
9.0x10-4] paretic, [-0.019, -4.3x10-4] non-paretic).  257 
 258 
--- [Fig. 3] --- 259 
 260 
Changes in CME are presented from the paretic RF and TA muscles in Fig. 3F. We were able to 261 
elicit MEPs in the RF muscle in 11 of the 12 participants. Average excitability of the paretic RF 262 
increased by 20.8% (SEM 11.2), though this was non-significant (p=0.095; 95% CI = [-3.9, 41.9] 263 
%). Of the 11 participants, nine showed an increase in the MEP amplitude with the device ON 264 
compared to when the SMA was OFF. This increase in MEP amplitude ranged from 2% to 90%, 265 
indicating a high variability in CME in response to the exoskeleton assistance. We were able to 266 
evoke an MEP from the TA in 10 of the 12 participants. Average excitability of the paretic TA 267 
decreased by 14.8% (SEM 10.9), though this was non-significant (p=0.18; 95% CI = [-34.5, 7.5] 268 
%). Of the 10 participants, seven showed a decrease in the MEP amplitude with the device ON 269 
compared to when the SMA was OFF. Two participants showed small increases, and one showed 270 
a large increase in MEP amplitude with the device ON.  271 
 272 
Discussion 273 
Over a single session of use with the SMA hip device, we found significant improvements in 274 
measures of walking performance in chronic stroke patients. Self-selected walking speed and 275 
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spatiotemporal gait symmetry increased with SMA use. Our results also indicate that assistance 276 
from the SMA enabled patients to maintain a higher rate of speed while consuming less oxygen. 277 
These findings confirm that a hip-assistive exoskeleton elicits an immediate impact or adaptation 278 
on walking and functional capabilities in individuals with chronic stroke and mild-moderate gait 279 
impairments. 280 
 281 
The cross-over study design, in which measures were taken with the device OFF and ON, was 282 
selected to minimize the potential of a placebo effect of wearing a gait-assistive device designed 283 
by large commercial manufacturer such as Honda. The SMA in its ON mode increased self-284 
selected walking speed in these participants with mild-moderate gait impairment. Our previous 285 
work has shown that long-term SMA training specifically increases stride length while 286 
decreasing double support time and swing time [30]. Changes in walking speed were not 287 
observed in the fast velocity condition. 288 
 289 
During the graded treadmill test, participants were able to reach higher maximum walking speeds 290 
on the treadmill with the device in ON mode. Improvements in exercise capacity were 291 
substantiated by measures of energy efficiency, where the oxygen consumption rates were 292 
reduced in both the graded treadmill and six-minute walk tests. This has been shown previously 293 
in younger adults walking with the SMA over a single session [28]. Traditionally, increased 294 
metabolic demands during gait training has been noted as a limiting factor in the administration 295 
of physical therapy and rehabilitation [40-42]. This makes the SMA a promising 296 
exercise/therapeutic tool, since reducing the metabolic demand during strenuous gait training 297 
may enable greater walking-related gains post-stroke. Similarly, during the six-minute walk test, 298 
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most participants were able to walk farther distance with lower metabolic cost. This suggests that 299 
the future SMA may be useful as a walking-assistive personal mobility device, as it may 300 
encourage participants to walk more at home and in the community without the fear of fatigue 301 
and meeting the demands of navigating the community environment.  302 
 303 
Evaluations of kinematic behavior indicated improvements in spatiotemporal symmetry. This 304 
agrees with our previous findings of increased symmetry after long-term training with the SMA 305 
[30]. In the current study, these improvements were observable during single-session use of the 306 
SMA, suggesting the effects of the repetitive movement provided by the SMA has short-term 307 
kinematic benefits. Increases in ACC during the SMA in ON mode versus OFF mode reveal 308 
increased consistency between hip and knee angles on both the paretic and non-paretic sides. 309 
Higher ACC is strongly correlated to improved walking function [32, 43]. Walking with the 310 
SMA in ON mode also reduced FWHM on both the paretic and non-paretic sides, indicating 311 
more rhythmic and consistent stepping with the SMA torque assistance. This might be useful in 312 
training efficiency, as well as helping to prevent falls, which may be related to spatiotemporal 313 
asymmetry and inconsistent stepping patterns [44].  314 
 315 
Amplitude of motor evoked potentials increased more consistently for the rectus femoris muscle 316 
on the paretic side, which indicates that the SMA in ON mode increases corticomotor excitability 317 
of the damaged side of the brain. The consistent hip flexion motor and sensory assistance from 318 
the SMA resulted in potentially activating the damaged side of the cortex to increase its signal 319 
transmission. We have seen that long-term training with the SMA increases excitability of the 320 
paretic rectus femoris during voluntary contraction [29]. Conversely, neither this single session 321 
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nor long-term training affects corticomotor excitability of the tibialis anterior. An alternative 322 
exoskeleton design with assistance as the ankle joint may be required to elicit a more pronounced 323 
response for this muscle group. 324 
 325 
Comparison to MCID 326 
The MCID for a stroke population is suggested to be 0.06 m/s for walking speed (small 327 
meaningful change) [39] and 34.4 m for 6MWT [45]. Average changes in self-selected walking 328 
speed (0.05 m/s) and 6MWT distance (32.3 m) fell short of MCID for a single session of SMA 329 
use. At the individual level, three participants exceeded MCID for walking speed, and six 330 
participants exceeded MCID for 6MWT. Future work will compare single session adaptations 331 
with long-term training to further uncover the impact of SMA dosage on clinically-relevant 332 
outcomes and the predictors of response to this training. 333 
 334 
Study Limitations 335 
A major limitation of the current study is its small sample size with similar levels of gait 336 
impairment. It remains to be seen how the device affects walking function in a more impaired 337 
population, or in the subacute phase of stroke. Additionally, baseline measures, in which 338 
participants did not wear the exoskeleton, were not taken for all outcomes. We only measured 339 
self-selected walking speed at baseline, under the assumption that the SMA in OFF mode was 340 
equivalent SMA being off the body due to its light weight (2.8 kg). It is also possible that the 341 
training-induced changes in our MEP data were confounded by physiologic factors such as 342 
lesion location, muscle activity, alertness, or by technical factors such as intensity of stimulation 343 
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and location of coil, which would diminish our ability to detect changes in corticomotor 344 
excitability. 345 
 346 
Conclusions 347 
This study reveals that a single session of SMA use elicits immediate adaptations in clinical 348 
walking performance, walking energetics, and gait kinematics. Improvements in walking 349 
performance are seen both on the treadmill and over-ground walking function, along with 350 
improvements in stepping consistency and periodicity. Future work will further examine the 351 
time-course of adaptation and wash-out to the SMA across single and multiple training sessions, 352 
as well as the usability of the SMA in the home and community environment as an everyday 353 
personal mobility device. The immediate adaptations seen with the SMA allows clinicians to test 354 
the device with their patients during a single session and deem whether it is appropriate for them 355 
during therapy.  356 
 357 
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Figure Legends 
Figure 1: Experimental design. Participants were their own controls in this randomized cross-
over trial. Outcome measures were taken with the SMA device turned OFF and ON. 
 
Figure 2: Self-selected walking speed. SSV at baseline (without the SMA), with the SMA 
turned OFF, and with the SMA ON. Error bars represent SEM. 
 
Figure 3: Change in outcome measures between OFF and ON conditions. Percentage change 
in (A) walking speed in the SSV and FV conditions, (B) peak treadmill (TM) speed and distance 
walked during 6MWT, (C) maximum and average oxygen consumption rate during the graded 
TM test and 6MWT, respectively, (D) ACC of the paretic and non-paretic leg, (E) FWHM of the 
paretic and non-paretic leg, and (F) corticomotor excitability (CME) of the RF and TA. Error 
bars represent SEM. Asterisks (*) indicate significant difference between the ON and OFF 
conditions (paired t-tests). 
 
 
 Tables 
Table 1: Participant demographics at baseline 
ID 
Sex  
(M/F) 
Age 
(years) 
Stroke 
latency 
(years) 
Stroke type  
Side 
affected 
(R/L) 
Assistive 
Device Bracing 
Initial gait 
speed  
(m/s) 
S1 F 63 13 Unknown R Straight Cane AFO 0.36 
S2 M 65 14 Hemorrhagic R Quad Cane None 0.70 
S3 M 64 20 Hemorrhagic L Straight Cane AFO 0.36 
S4 M 48 10 Hemorrhagic L Straight Cane None 0.70 
S5 M 70 22 Hemorrhagic L None AFO 0.70 
S6 F 54 11 Ischemic L Straight Cane AFO 0.75 
S7 F 57 28 Ischemic R Straight Cane AFO 0.79 
S8 M 61 21 Hemorrhagic R   Straight Cane None 0.32 
S9 M 58 8 Hemorrhagic R None None 0.70 
S10 M 55 11 Ischemic R None None 0.75 
S11 F 54 12 Ischemic R None None 0.37 
S12 M 45 5 Unknown R None AFO 0.67 
 
Table 2: Changes in outcomes between SMA conditions (ON-OFF) 
ID 
SSV 
(m/s) 
FV 
(m/s) 6MWT 
Graded endurance 
test ACC 
FWHM 
 
  
Distance 
(m) 
VO2 avg 
(mL/kg/km) 
Peak vel 
(m/s) 
VO2 max 
(mL/kg/km) 
Non-
paretic Paretic 
Non-
paretic 
Paretic 
S1 0.05 -0.08 36.7 -10.46 0.1 0.04 0.148 0.073 -0.043 -0.035 
S2 0.26 0 39.9 -11.75 0.1 -0.01 0.113 0.024 -0.013 -0.013 
S3 0.03 0.03 -25.3 -122.76 0 -0.07 0.102 0.147 -0.010 -0.005 
S4 0.04 -0.03 34.3 -134.97 0.1 -0.20 0.104 0.124 -0.003 0.000 
S5 0.10 -0.20 63.0 28.19 0.1 -0.05 0.090 0.130 -0.003 -0.003 
S6 0.04 0.02 76.0 -49.55 0.2 -0.11 0.104 0.080 -0.023 -0.025 
S7 0.02 0.07 -37.0 -15.29 0.1 0.01 0.150 0.043 -0.005 -0.008 
S8 0.01 0.18 -30.8 -51.06 0.2 -0.43 0.094 0.032 0.020 0.015 
S9 0.07 0.03 14.0 -38.57 0.1 -0.01 0.078 -0.023 -0.010 -0.010 
S10 0.01 -0.10 11.1 -5.59 0.1 -0.02 0.103 0.010 -0.010 -0.008 
S11 0.01 0.05 157.3 -39.16 0.1 -0.03 0.097 0.037 -0.013 -0.010 
S12 0.01 0.03 49.0 31.92 0.1 0.01 0.097 0.079 -0.005 -0.005 
Mean 
(SEM) 
0.05 
(0.02) 
0.00 
(0.03) 
32.3 
(15.5) 
-34.92 
(14.84) 
0.11 
(0.02) 
-0.08 
(0.04) 
0.104 
(0.006) 
0.064 
(0.015) 
-0.010 
(0.004) 
-0.009 
(0.003) 
 



